Kei Muro

Summary

Affiliation: Aichi Cancer Center
Country: Japan

Publications

  1. doi request reprint Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
    Kei Muro
    Department of Clinical Oncology, Aichi Cancer Centre Hospital, Chikusa ku, Nagoya, Japan
    Lancet Oncol 11:853-60. 2010
  2. doi request reprint A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer
    Kei Muro
    Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
    Jpn J Clin Oncol 39:321-6. 2009
  3. doi request reprint Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi Prefecture 464 8681, Japan
    Invest New Drugs 30:787-93. 2012
  4. doi request reprint Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi, 464 8681, Japan
    Gastric Cancer 16:48-55. 2013
  5. doi request reprint Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy
    Motoo Nomura
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan
    Int J Radiat Oncol Biol Phys 82:946-52. 2012
  6. ncbi request reprint Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer
    Tomoya Yokota
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Anticancer Res 31:3535-41. 2011
  7. doi request reprint A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi, 464 8681, Japan
    Int J Clin Oncol 18:539-46. 2013
  8. doi request reprint Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Oncology 81:167-74. 2011
  9. doi request reprint Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    Gastric Cancer 14:155-60. 2011
  10. ncbi request reprint Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan
    Asian Pac J Cancer Prev 11:447-52. 2010

Detail Information

Publications46

  1. doi request reprint Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
    Kei Muro
    Department of Clinical Oncology, Aichi Cancer Centre Hospital, Chikusa ku, Nagoya, Japan
    Lancet Oncol 11:853-60. 2010
    ....
  2. doi request reprint A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer
    Kei Muro
    Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
    Jpn J Clin Oncol 39:321-6. 2009
    ..This Phase 2 study evaluated efficacy, pharmacokinetics and safety of panitumumab in Japanese patients with mCRC who developed progressive disease during or after fluoropyrimidine, irinotecan and oxaliplatin chemotherapy...
  3. doi request reprint Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi Prefecture 464 8681, Japan
    Invest New Drugs 30:787-93. 2012
    ..0%) and one treatment related death due to pneumonia was observed. Combination chemotherapy with biweekly cetuximab and irinotecan was effective for pretreated metastatic colorectal cancer with wild-type KRAS...
  4. doi request reprint Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi, 464 8681, Japan
    Gastric Cancer 16:48-55. 2013
    ..There are few data on the efficacy of combination chemotherapy with a fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer (AGC) complicated by peritoneal metastasis, especially massive ascites...
  5. doi request reprint Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy
    Motoo Nomura
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan
    Int J Radiat Oncol Biol Phys 82:946-52. 2012
    ..The objective of this study was to evaluate the prognostic impact of the new staging system on esophageal cancer patients treated with CRT...
  6. ncbi request reprint Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer
    Tomoya Yokota
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Anticancer Res 31:3535-41. 2011
    ..This study aimed to evaluate the efficacy of docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer...
  7. doi request reprint A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi, 464 8681, Japan
    Int J Clin Oncol 18:539-46. 2013
    ..On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC...
  8. doi request reprint Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Oncology 81:167-74. 2011
    ..The ability of molecular targeting agents to improve overall survival (OS) in metastatic colorectal cancer (MCRC) patients who underwent oxaliplatin-based chemotherapy remains controversial...
  9. doi request reprint Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    Gastric Cancer 14:155-60. 2011
    ....
  10. ncbi request reprint Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan
    Asian Pac J Cancer Prev 11:447-52. 2010
    ..The purpose of this analysis was to evaluate the impact of genetic polymorphisms of the ABCB1 gene on clinical outcomes in patients with advanced gastric cancer (AGC) treated with second-line chemotherapy...
  11. doi request reprint Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Oncology 79:211-8. 2010
    ..However, these studies included patients able to maintain sufficient oral intake, and the effectiveness of chemotherapy for patients unable to eat remained unclear...
  12. doi request reprint Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Eur J Cancer 47:2673-80. 2011
    ....
  13. ncbi request reprint Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer
    Chihiro Kondoh
    Dept of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Gan To Kagaku Ryoho 39:1511-5. 2012
    ..Although there appears to be incomplete cross-resistance between docetaxel and paclitaxel in several types of malignancies, to our best knowledge there have been no available data on this for advanced gastric cancer...
  14. doi request reprint A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy
    Ayako Mizota
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Oncology 81:237-42. 2011
    ..To retrospectively compare docetaxel (DTX) with paclitaxel (PTX) with regard to efficacy and safety in advanced or recurrent esophageal cancer patients who previously received platinum-based chemotherapy...
  15. doi request reprint Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, 464 8681, Aichi, Japan
    Invest New Drugs 29:688-93. 2011
    ..1 months. Grade 2 skin toxicity was observed in 23 patients, while no grade 3 skin toxicity was observed. Combined irinotecan and cetuximab is effective for pretreated metastatic wild-type KRAS colorectal cancer...
  16. doi request reprint A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab
    Ayako Mizota
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Int J Clin Oncol 16:766-9. 2011
    ..This case suggests that reintroduction of combination chemotherapy with FOLFOX plus bevacizumab is effective and feasible in patients with colorectal cancer with DIC and that chemotherapy may be a treatment option for such patients...
  17. doi request reprint Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer
    Ayako Mizota
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 0011, Japan
    Int J Clin Oncol 16:416-20. 2011
    ..The efficacy and safety of cetuximab for irinotecan-intolerant patients has not yet been evaluated in detail...
  18. doi request reprint Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Jpn J Clin Oncol 40:699-701. 2010
    ..The primary endpoint is response rate. The secondary endpoints include adverse events, progression-free survival and overall survival. The pharmacokinetics of cetuximab will also be evaluated in five patients...
  19. ncbi request reprint FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases
    Ayako Mizota
    Dept of Clinical Oncology, Aichi Cancer Center Hospital, Japan
    Gan To Kagaku Ryoho 38:1205-8. 2011
    ..Combination chemotherapy with mFOLFOX6 plus cetuximab was effective and feasible in this case of metastatic colon cancer with icterus due to diffuse liver metastasis...
  20. doi request reprint Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Gastric Cancer 16:261-7. 2013
    ..The purpose of this study was to evaluate the impact of human epidermal growth factor receptor 2 (HER2) status and trastuzumab treatment on the prognosis of patients with advanced gastric cancer (AGC)...
  21. doi request reprint Recursive partitioning analysis for new classification of patients with esophageal cancer treated by chemoradiotherapy
    Motoo Nomura
    Department of Radiology, Kansai Medical University, Hirakata, Japan Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Int J Radiat Oncol Biol Phys 84:786-92. 2012
    ....
  22. doi request reprint Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Cancer Chemother Pharmacol 68:301-7. 2011
    ..We performed a systematic review and meta-analysis to determine the impact of neutropenia or leukopenia experienced during chemotherapy on survival...
  23. doi request reprint Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
    Jpn J Clin Oncol 41:663-5. 2011
    ..In this case, trastuzumab plus lapatinib resulted in durable stable disease, despite the appearance of progression during prior chemotherapy with trastuzumab...
  24. doi request reprint Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
    Eur J Cancer 45:1757-63. 2009
    ..Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy...
  25. doi request reprint Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 8681, Aichi, Japan
    Invest New Drugs 30:1224-31. 2012
    ..Further research is needed to clarify the surrogacy of PFS/TTP for OS or the role of PFS as the true end point in future randomized clinical trials of chemotherapy for AGC...
  26. ncbi request reprint [Transition of chemotherapy for metastatic colorectal cancer and recent advances]
    Kei Muro
    Department of Clinical Oncology, Aichi Cancer Center Hospital
    Nihon Rinsho 68:1143-9. 2010
    ..By continued advances in pharmaceutical development combined with appropriate use of liver resection, we hope that these gains may be amplified and extended to further improve patient survival...
  27. doi request reprint Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, and Department of Epidemiology, Nagoya University Graduate School of Medicine, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
    Cancer Epidemiol Biomarkers Prev 19:1311-9. 2010
    ..However, to our knowledge, there are no reports that evaluate simultaneously the effects of folate intake and genetic polymorphisms on clinical outcome of gastric cancer patients...
  28. doi request reprint Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
    Jpn J Clin Oncol 41:287-90. 2011
    ..The primary endpoint is overall survival. Secondary endpoints include progression-free survival, response rate, disease control rate and adverse events...
  29. doi request reprint Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain
    Motoo Nomura
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Clin J Pain 29:487-91. 2013
    ..A secondary objective was to identify an association between serum albumin and the absorption of fentanyl from the transdermal patch...
  30. doi request reprint Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    Gastric Cancer 15:137-43. 2012
    ..There is no consensus on which patient characteristics are the most suitable to report or to be used as stratification factors in clinical trials for advanced gastric cancer (AGC), to our knowledge...
  31. pmc Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Case Rep Oncol 3:282-6. 2010
    ..Therefore, FOLFOX plus cetuximab is suspected to be the best regimen to alleviate tumor-related symptoms with a high response rate...
  32. ncbi request reprint [Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey]
    Yumiko Sato
    Department of Pharmacy, West Medical Center Municipal Hospital, Nagoya, Japan
    Yakugaku Zasshi 131:1661-6. 2011
    ..Information on such predictive factors should be useful to promote the effectiveness of cancer chemotherapy...
  33. doi request reprint Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
    Jpn J Clin Oncol 38:786-9. 2008
    ..3 versus 2.3 months, P = 0.02). S-1-containing chemotherapy does not appear to be effective in patients whose gastric cancer recurs after adjuvant S-1 chemotherapy. Other chemotherapeutic agents should be evaluated in this setting...
  34. doi request reprint Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Cancer Sci 101:1001-6. 2010
    ..Further investigation is warranted to explain this different prognosis...
  35. doi request reprint Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer
    Tomoya Yokota
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Kanokoden, Chikusa ku, Nagoya, Japan
    Transl Res 156:98-105. 2010
    ..In conclusion, cycleave PCR is practically applicable to KRAS/BRAF genotyping using small amounts of biopsied tumor cells. Care must be taken in the selection of pathological specimens for KRAS/BRAF testing...
  36. ncbi request reprint Central venous access port-related complications in outpatient chemotherapy for colorectal cancer
    Yoshitaka Inaba
    Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, 1 1Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Jpn J Clin Oncol 37:951-4. 2007
    ..The port system has been placed more frequently since the approval of FOLFOX. Consequently, more complications involving ports and pumps have been encountered...
  37. doi request reprint Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Aichi, Japan
    Jpn J Clin Oncol 41:814-6. 2011
    ..In this case, treatment with everolimus resulted in dramatic tumor response for the malignant epithelioid variant of angiomyolipoma...
  38. ncbi request reprint [Molecular targeted therapy in colorectal cancer and its resistance]
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
    Gan To Kagaku Ryoho 36:557-66. 2009
    ..Further basic research and biomarker analysis of large clinical study are necessary to clarify the resistance to molecular targeting agents...
  39. doi request reprint Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study
    Atsushi Ohtsu
    Atsushi Ohtsu, National Cancer Center Hospital East, Kashiwa Keisho Chin, Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan Jaffer A Ajani, University of Texas MD Anderson Cancer Center, Houston, TX Tarek Sahmoud, Heind Smith, Syed Rizvi, David Lebwohl, Novartis Pharmaceuticals, Florham Park, NJ Yu Xian Bai, Tumor Hospital of Harbin Medical University, Harbin Hong Ming Pan, Sir Run Run Shaw Hospital, Zhejiang Lin Shen, Peking University Cancer Hospital, Beijing, People s Republic of China Yung Jue Bang, Seoul National University College of Medicine Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine Yeul Hong Kim, Korea University Anam Hospital, Seoul, South Korea Kun Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan, Republic of China David Ferry, New Cross Hospital, Wolverhampton, United Kingdom Niall C Tebbutt, Austin Health, Heidelberg, Germany
    J Clin Oncol 31:3935-43. 2013
    ..This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in previously treated advanced gastric cancer...
  40. doi request reprint Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese
    Keitaro Matsuo
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    Int J Cancer 125:1961-4. 2009
    ..No association was seen between PSCA polymorphisms and H. pylori infection. In conclusion, PSCA polymorphisms are associated with stomach cancer risk in Japanese. A possible interaction with family history warrants further evaluation...
  41. doi request reprint CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Yukiya Narita
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi, 464 8681, Japan
    Cancer Chemother Pharmacol 73:409-16. 2014
    ..We reviewed all mCRC patients at a single institution to evaluate the relationship between CA19-9 levels and survival...
  42. doi request reprint Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients
    Narikazu Boku
    Department of Clinical Oncology, St Marianna University School of Medicine, 2 16 1, Sugao, Miyamae ku, Kawasaki 216 8511, Japan
    Jpn J Clin Oncol 44:214-23. 2014
    ..We conducted a post-marketing surveillance study to evaluate the safety and effectiveness of panitumumab...
  43. ncbi request reprint [Team medicine in chemotherapy for metastatic colorectal cancer]
    Kei Muro
    Department of Clinical Oncology, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    Gan To Kagaku Ryoho 40:435-9. 2013
    ..I would like to mention the attempt of Aichi Prefecture which has launched a system to support the team medicine through multicenter, multidisciplinary, and regional cooperation...
  44. doi request reprint Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer
    Narikazu Boku
    Department of Clinical Oncology, St Marianna University School of Medicine, 2 16 1, Sugao, Miyamae ku, Kawasaki, Kanagawa, 216 8511, Japan
    Invest New Drugs 32:261-70. 2014
    ..This phase I, dose-finding study evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of sunitinib plus S-1/cisplatin in Japanese patients with advanced/metastatic gastric cancer...
  45. pmc Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives
    Kohei Shitara
    Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    Gastrointest Cancer Res 3:66-72. 2009
    ..Additional studies are necessary to further elucidate this multimodality approach. Current treatment strategies for esophageal cancer and research initiatives in Japan are reviewed...
  46. ncbi request reprint [mTOR inhibitor]
    Kei Muro
    Dept of Clinical Oncology, Aichi Cancer Center Hospital, Japan
    Gan To Kagaku Ryoho 38:7-11. 2011
    ..The usefulness of mTOR has also been shown in pancreatic neuroendocrine tumor. The next task is to discover a clinically effective biomarker that predicts effect and toxicity of mTOR...